NCT06759363View on ClinicalTrials.gov

MASLD Butyrate Supplementation Treatment Efficacy Review

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

January 20, 2025

Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
DRUG

Sodium-Butyrate

1000 mg/day of sodium-butyrate

DRUG

Calcium Butyrate

1000 mg/day of calcium-butyrate

Trial Locations (1)

11000

University Medical Center Zvezdara, Belgrade

All Listed Sponsors
lead

University Medical Center Zvezdara

OTHER